Get on the path to relief, oklahoma.
Don't live in pain- overcome it with arthokinex.
The Arthrokinex Joint Health Program is year-long, physician directed and supervised program that combines cutting-edge technology with the body’s natural ability to heal. Using the patient’s blood, Arthrokinex processes the blood through a series of centrifuge cycles to isolate Interluekin 1-Ra, an inflammation-fighting protein that block the aggressive messenger protein, Interleukin-1. A serum is creating using the Interleukin 1-Ra and can be introduced to the affected joint(s) immediately. Any joint can be treated with Arthrokinex (IL-1 Ra) and multiple joints can be treated simultaneously. More than 81% of patient’s report dramatic pain relief, improved range of motion and, improved quality of life following the first injection. Arthrokinex (IL-1 Ra) is medically proven to be the best joint pain treatment on the market. Some patients even experience relief after their last treatment for up to two years.
Our clinics are located in Oklahoma City, Norman, and Tulsa. We look forward to providing you with an all-natural, comprehensive approach to joint pain relief.
Don't live in pain. Give us a call today!
ARTHROKINEX PRESS RELEASE
aRTHROKINEX FEATURED IN JOURNALS
A Method to Induce Interleukin-1 Receptor Antagonist Protein from Autologous Whole Blood
Current orthopedic therapies, aimed solely at symptomatic control, are unable to restore the cytokine imbalance that produces the hallmark clinical profile of osteoarthritis. While a myriad of chemical factors in the cytokine network stimulate local joint inflammation and pain, Interleukin 1 (IL-1) is widely recognized as a key offender and a potential therapeutic target. The purpose of this article is to describe a novel, on-site, point of service process (Arthrokinex™) to induce Interleukin 1 Receptor Antagonist Protein (IL-1-Ra or IRAP)...
Journal of Orthopaedics
A New Treatment for Knee Osteoarthritis: Clinical Evidence for the Efficacy of Arthrokinex™ Autologous Conditioned Serum
The desired therapeutic effect of Arthrokinex™ autologous conditioned serum (ACS) is facilitated by the ability of IL-1-Ra to limit the destructive inflammatory intra-articular (IA) actions of IL- 1b. Previous studies have proven the capacity of Arthrokinex™(ACS) to induce the anti-inflammatory cytokine, IL-1-Ra. The primary purpose of this retrospective study was to investigate the effect of Arthrokinex™ (ACS) to reduce pain, improve joint function and enhance quality of life in patients with knee osteoarthritis...